Pharmacotherapy prescribing pattern and outcome for hospitalized patients with severe and critical COVID-19

1. Phelan AL, Katz R, Gostin LO. The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. JAMA. 2020;323(8):709-10.10.1001/jama.2020.109731999307 Search in Google Scholar

2. Al-Malkey MK, Al-Sammak MA. Incidence of the COVID-19 in Iraq – Implications for travellers. Travel Med Infect Dis. 2020;38:101739.10.1016/j.tmaid.2020.101739721936332405265 Search in Google Scholar

3. WHO; 2021. [https://covid19.who.int/] (access: 04 June 2021) Search in Google Scholar

4. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061-9.10.1001/jama.2020.1585704288132031570 Search in Google Scholar

5. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020;323(20):2052-9.10.1001/jama.2020.6775717762932320003 Search in Google Scholar

6. Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB. Pharmacologic treatments for Coronavirus Disease 2019 (COVID-19): A review. JAMA. 2020;323(18):1824-36.10.1001/jama.2020.601932282022 Search in Google Scholar

7. Bajwah S, Wilcock A, Towers R, Costantini M, Bausewein C, Simon ST, et al. Managing the supportive care needs of those affected by COVID-19. Eur Respir J. 2020;55(4):2000815.10.1183/13993003.00815-2020714426832269090 Search in Google Scholar

8. Campos DM de O, Fulco UL, de Oliveira CBS, Oliveira JIN. SARSCoV-2 virus infection: Targets and antiviral pharmacological strategies. J Evid Based Med. 2020;13(4):255-60.10.1111/jebm.12414767531533058394 Search in Google Scholar

9. Sahebnasagh A, Avan R, Saghafi F, Mojtahedzadeh M, Sadremomtaz A, Arasteh O, et al. Pharmacological treatments of COVID-19. Pharmacol Rep. 2020;72:1446-78.10.1007/s43440-020-00152-9743963932816200 Search in Google Scholar

10. Chappell L, Horby P, Lim WS, Emberson JR, Mafham M, Bell JL, et al. Dexamethasone in hospitalized patients with COVID-19 – preliminary report. N Engl J Med. 2021;384(8):693-704.10.1056/NEJMoa2021436738359532678530 Search in Google Scholar

11. Kewan T, Covut F, Al-Jaghbeer MJ, Rose L, Gopalakrishna KV, Akbik B. Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study. E Clinical Medicine. 2020;24:100418.10.1016/j.eclinm.2020.100418730550532766537 Search in Google Scholar

12. WHO; 2021.[https://www.who.int/] (access: 28 June 2021) Search in Google Scholar

13. Best JH, Kong AM, Kaplan-Lewis E, Brawley OW, Baden R, Zazzali JL, et al. Treatment patterns in US patients hospitalized with COVID-19 and pulmonary involvement. J Med Virol. 2021;93:5367-75.10.1002/jmv.27049 Search in Google Scholar

14. Chibber P, Haq SA, Ahmed I, Andrabi NI, Singh G. Advances in the possible treatment of COVID-19: A review. Eur J Pharmacol. 2020;883:173372.10.1016/j.ejphar.2020.173372 Search in Google Scholar

15. Lin KJ, Schneeweiss S, Tesfaye H, D’Andrea E, Liu J, Lii J, et al. Pharmacotherapy for hospitalized patients with COVID-19: Treatment patterns by disease severity. Drugs. 2020;80(18):1961-72.10.1007/s40265-020-01424-7 Search in Google Scholar

16. Centers for Disease Control and Prevention. Guidance for COVID-19. [https://www.cdc.gov/coronavirus/2019-ncov/communication/guidance.html] (access: 27 June 0 2021). Search in Google Scholar

17. Watanabe JH, Kwon J, Nan B, Abeles SR, Jia S, Mehta SR. Medication use patterns in hospitalized patients with COVID-19 in California During the pandemic. JAMA Netw Open. 2021;4(5):e2110775.10.1001/jamanetworkopen.2021.10775 Search in Google Scholar

18. Beigel JH, Tomashek KM, Dodd LE, Mehta AK, Zingman BS, Kalil AC, et al. Remdesivir for the treatment of COVID-19 – Final Report. N Engl J Med. 2020;383(19):1813-26.10.1056/NEJMoa2007764 Search in Google Scholar

19. Wang Y, Zhang D, Du G, Du R, Zhao J, Jin Y, et al. Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020;395(10236):1569-78.10.1016/S0140-6736(20)31022-9 Search in Google Scholar

20. Rattanaumpawan P, Jirajariyavej S, Lerdlamyong K, Palavutitotai N, Saiyarin J. Real-world experience with favipiravir for treatment of COVID-19 in Thailand: Results from a multi-center observational study. MedRxiv. 2020. [https://doi.org/10.1101/2020.06.24.20133249]10.1101/2020.06.24.20133249 Search in Google Scholar

21. Salazar E, Christensen PA, Graviss EA, Nguyen DT, Castillo B, Chen J, et al. Treatment of Coronavirus Disease 2019 patients with convalescent plasma reveals a signal of significantly decreased mortality. Am J Pathol. 2020;190(11):2290-303.10.1016/j.ajpath.2020.08.001741790132795424 Search in Google Scholar

22. Alsharidah S, Ayed M, Ameen RM, Alhuraish F, Rouheldeen NA, Alshammari FR, et al. COVID-19 convalescent plasma treatment of moderate and severe cases of SARS-CoV-2 infection: A multicenter interventional study. Int J Infect Dis. 2021;103:439-46.10.1016/j.ijid.2020.11.198771777233285283 Search in Google Scholar

23. Arshad S, Kilgore P, Chaudhry ZS, Jacobsen G, Wang DD, Huitsing K, et al. Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19. Int J Infect Dis. 2020;97:396-403.10.1016/j.ijid.2020.06.099733057432623082 Search in Google Scholar

24. Freedberg DE, Conigliaro J, Wang TC, Tracey KJ, Callahan MV, Abrams JA, et al. Famotidine use is associated with improved clinical outcomes in hospitalized COVID-19 patients: A propensity score matched retrospective cohort study. Gastroenterol. 2020;159(3):1129-31.e3.10.1053/j.gastro.2020.05.053724219132446698 Search in Google Scholar

25. Padhy BM, Mohanty RR, Das S, Meher BR. Therapeutic potential of ivermectin as add on treatment in COVID 19: A systematic review and meta-analysis. J Pharm Pharm Sci. 2020;23:462-9.10.18433/jpps3145733227231 Search in Google Scholar

26. Zanasi A, Mazzolini M, Kantar A. A reappraisal of the mucoactive activity and clinical efficacy of bromhexine. Multidiscip Respir Med. 2017;12(1):1-14.10.1186/s40248-017-0088-1535981728331610 Search in Google Scholar